

## **Statement from NICE on Osteoporosis Guideline**

On 9 June 2010 NICE staff involved with the technology appraisals and clinical guideline on osteoporosis met members of the National Osteoporosis Society. The current status of the judicial review of the osteoporosis technology appraisals, in particular the reconsideration of the strontium ranelate recommendation, was summarised. The technical difficulties in progressing the clinical guideline, including the implications of the recently agreed Pharmaceutical Price Regulation Scheme on the funding directive when appraisals are updated in clinical guidelines, were also discussed. It was agreed that there was still a need for the NHS to have more guidance on osteoporosis, especially around risk assessment.

Following the meeting NICE agreed that it would take forward plans to develop a short clinical guideline on risk assessment of patients with osteoporosis. On 21 September 2010, the Department of Health formally agreed to the referral of a short clinical guideline on risk assessment, instead of the full clinical guideline.

As a result the original clinical guideline development group has been formally stood down.

NICE held a meeting on 30 September 2010 – for the independent experts and patient representatives who have been hitherto directly involved in the guideline development process – at which all of these matters were described in more detail.

When it is available, further information on the production of the short clinical guideline will be provided on the NICE website.